Sunshine Biopharma Q2 net loss narrows 11.67% to $1.56 million; revenue slips 1.6% to $9.26 million - SBFM News | RalliesSunshine Biopharma Q2 net loss narrows 11.67% to $1.56 million; revenue slips 1.6% to $9.26 million
S
SBFM• Quarterly results
- Sunshine Biopharma posted a net loss of $1.56 million, or $1.15 per share, in the quarter ended June 30, 2026.
- Revenue slipped 1.6% to $9.26 million from a year earlier, due to distribution agreements ending Dec. 31, 2025.
Margins and expenses
- Gross profit fell to $2.43 million, cutting gross margin by 10.2 percentage points to 26.2% on higher costs.
- Operating loss narrowed to $1.61 million as general and administrative expenses dropped to $4.04 million.
Cash position and outlook
- Cash and cash equivalents were $13.75 million at June 30, 2026.
- The company said it forecasts funding for the next 27 months.
MGRX
•
